BioSpace News Archive

Apex files phase 2a Clinical Trial Application with Health Canada and announces Series A financing.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today it will build on the content of its completed 510(k) application and pursue the De Novo pathway for its TAEUS System, which is intended to characterize fatty liver tissue as a means to non-invasively assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD).

Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into agreements to create a comprehensive strategic relationship with Ascension, one of the nation’s leading Catholic and non-profit health systems.

Shattuck Labs, Inc. announced that company management will participate in the 11th Annual SVB Leerink Global Healthcare Conference being held February 14-18, 2022.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), today announced the presentation of clinical safety data supporting the first-generation construct at the highest dose of 1.0x1015 total vg for the treatment of CLN7 Batten disease at the 18th Annual WORLD Symposium.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing niche generic products, announced that the third quarter financial results of the 2022 fiscal year will be released on Monday, February 14, 2022.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine.

Statera Biopharma, Inc., a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced the closing of its previously announced registered direct offering with a certain institutional investor, pursuant to which the Company sold $2.0 million worth of its common stock and warrants.

Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-launched Managed Access Program.

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial results and provided a business update for the three-month period ended December 31, 2021.